{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:58:46Z","timestamp":1759694326081},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T00:00:00Z","timestamp":1357689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0053459","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T19:05:39Z","timestamp":1357758339000},"page":"e53459","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine"],"prefix":"10.1371","volume":"8","author":[{"given":"Heidi N.","family":"Boyda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine C. Y.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen Helen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"RM Procyshyn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fpsyt.2012.00062","article-title":"Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs","volume":"3","author":"JM Gohlke","year":"2012","journal-title":"Front Psychiatry"},{"key":"ref3","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"RM Procyshyn","year":"2007","journal-title":"J Psychiatry Neurosci"},{"key":"ref4","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"JW Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.0208e04","article-title":"Managing weight gain and metabolic issues in patients treated with atypical antipsychotics","volume":"69","author":"DC Henderson","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0028-1085438","article-title":"Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial","volume":"42","author":"T Baptista","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","article-title":"Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study","volume":"113","author":"E Carrizo","year":"2009","journal-title":"Schizophr Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"JY Leung","year":"2012","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2010.12.007","article-title":"Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study","volume":"126","author":"CH Liao","year":"2011","journal-title":"Schizophr Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain","volume":"22","author":"T Baptista","year":"2008","journal-title":"CNS Drugs"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, <etal>et al<\/etal>.. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res.","DOI":"10.1016\/j.schres.2010.07.012"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14740338.2012.683523","article-title":"Safety and tolerability of antipsychotic polypharmacy","volume":"11","author":"JA Gallego","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"ref13","first-page":"27","article-title":"Risk-benefit analysis of available treatments for schizophrenia","volume":"1","author":"L Citrome","year":"2007","journal-title":"Psychiatric Times"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"RS Kahn","year":"2008","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0091270010368678","article-title":"Effect of antipsychotic medications on glucose and lipid levels","volume":"51","author":"PS Chaggar","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"S Skrede","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"JW Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"VL Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2008-1815","article-title":"Effects of olanzapine and haloperidol on the metabolic status of healthy men","volume":"95","author":"S Vidarsdottir","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"J Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"HN Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"M Hahn","year":"2011","journal-title":"Schizophr Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"KJ Davey","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain","volume":"7","author":"K Weston-Green","year":"2012","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"GC Smith","year":"2008","journal-title":"Diabetologia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"HN Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"KL Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model","volume":"108","author":"AF Chintoh","year":"2009","journal-title":"Schizophr Res"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, <etal>et al<\/etal>.. (2011) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl).","DOI":"10.1007\/s00213-011-2397-y"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"J Ferno","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"K Weston-Green","year":"2011","journal-title":"Behav Brain Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3810\/pgm.2011.03.2273","article-title":"Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics","volume":"123","author":"L Citrome","year":"2011","journal-title":"Postgrad Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"T Baptista","year":"2002","journal-title":"Brain Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2009.09.034","article-title":"Sensitivity of the female rat to olanzapine-induced weight gain\u2013far from the clinic?","volume":"116","author":"K Weston-Green","year":"2010","journal-title":"Schizophr Res"},{"key":"ref35","unstructured":"National Research Council (US) (2011) Committee for the Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academies Press. 8<sup>th<\/sup> Edition."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"HN Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/j.1460-9568.2008.06233.x","article-title":"Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins","volume":"27","author":"AM Barr","year":"2008","journal-title":"Eur J Neurosci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.0953-816X.2004.03457.x","article-title":"Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia","volume":"20","author":"AM Barr","year":"2004","journal-title":"Eur J Neurosci"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1152\/ajpendo.90889.2008","article-title":"Surrogate measures of insulin resistance: of rats, mice, and men","volume":"296","author":"K Mather","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref40","first-page":"110140","article-title":"Boyda HN, Procyshyn RM, Tse L, Hawkes E, Jin CH, et al. (In Press) Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","journal-title":"J Psychiatry Neurosci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"VL Albaugh","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"AF Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"PJ Martins","year":"2011","journal-title":"Diabetes"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Smith GC, Vickers MH, Shepherd PR (2011) Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem.","DOI":"10.3109\/13813455.2011.576681"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-009-1593-5","article-title":"Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats","volume":"206","author":"M Victoriano","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats","volume":"181","author":"GD Cooper","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2006.09.009","article-title":"Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain","volume":"551","author":"BM Patil","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1301\/nr.2003.dec.397-412","article-title":"Evaluation of insulin sensitivity in clinical practice and in research settings","volume":"61","author":"LU Monzillo","year":"2003","journal-title":"Nutr Rev"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1152\/ajpendo.00645.2007","article-title":"Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage","volume":"294","author":"R Muniyappa","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","article-title":"Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials","volume":"28","author":"PJ Weiden","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia","volume":"28","author":"AJ Cutler","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/JCP.0b013e318169cca7","article-title":"Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia","volume":"28","author":"JM Kane","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","article-title":"Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study","volume":"126","author":"RS McIntyre","year":"2010","journal-title":"J Affect Disord"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","article-title":"Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia","volume":"32","author":"RW Buchanan","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","article-title":"A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states","volume":"11","author":"RS McIntyre","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia","volume":"30","author":"JM Kane","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Dubovsky SL, Frobose C, Phiri P, Greef R, Panagides J (2011) Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry.","DOI":"10.1002\/gps.2737"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"V Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/JCP.0b013e3181fab7ca","article-title":"A comparison of antipsychotic drug-defined daily doses versus chlorpromazine equivalent doses in patients with or without extrapyramidal motor symptoms","volume":"30","author":"AM Barr","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.schres.2007.11.027","article-title":"Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment","volume":"100","author":"AM Barr","year":"2008","journal-title":"Schizophr Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1176\/ps.62.6.pss6206_0682a","article-title":"Excessive antipsychotic dosing in a Canadian outpatient population","volume":"62","author":"AM Barr","year":"2011","journal-title":"Psychiatr Serv"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"S Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"DL Braff","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-007-0973-y","article-title":"Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia","volume":"196","author":"O Franberg","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00213-010-2091-5","article-title":"Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism","volume":"214","author":"S Snigdha","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00213-009-1570-z","article-title":"Asenapine effects in animal models of psychosis and cognitive function","volume":"206","author":"HM Marston","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/jm00007a009","article-title":"3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2\/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873)","volume":"38","author":"JT Strupczewski","year":"1995","journal-title":"J Med Chem"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2006.04.004","article-title":"Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats","volume":"51","author":"AM Barr","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02246096","article-title":"Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine","volume":"122","author":"VP Bakshi","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.clinthera.2006.06.008","article-title":"A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg\/d oral olanzapine relative to 20 mg\/d oral olanzapine in stable psychiatric subjects","volume":"28","author":"M Mitchell","year":"2006","journal-title":"Clin Ther"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"JP McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"JW Newcomer","year":"2002","journal-title":"Arch Gen Psychiatry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0053459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:22:26Z","timestamp":1562545346000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0053459"}},"subtitle":[],"editor":[{"given":"Frederick G.","family":"Hamel","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,9]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0053459","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,9]]}}}